^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | DT-061 (PP2A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PP2A-activating drugs enhance FLT3 inhibitor efficacy through AKT inhibition-dependent GSK-3ß-mediated c-Myc and Pim-1 proteasomal degradation
Published date:
02/10/2021
Excerpt:
...co-treatment of FLT3-ITD-expressing cells with FLT3 inhibitors and PP2A-activating drug (PADs), which are in development. PADs, including FTY720 and DT-061, enhanced FLT3 inhibitor growth suppression and apoptosis induction in FLT3-ITD-expressing cell lines and primary AML cells in vitro and MV4-11 growth suppression in vivo.
Secondary therapy:
FLT3 inhibitor
DOI:
10.1158/1535-7163.MCT-20-0663
